THERAPEUTICSMD, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$893K
↑+33.9% +$226Kvs FY2024 (Q4)
Gross Profit
$893K
↑+33.9% +$226Kvs FY2024 (Q4)
Operating Income
$796K
↑+40.4% +$229Kvs FY2024 (Q4)
Net Income
$764K
↑+55.6% +$273Kvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $893K | $667K |
| COGS | $0 | $0 |
| Gross Profit | $893K | $667K |
| R&D | $0 | $0 |
| SG&A | $0 | $0 |
| D&A | $97K | $100K |
| Other OpEx | $0 | $0 |
| Operating Income | $796K | $567K |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $796K | $567K |
| Tax | $32K | $76K |
| Net Income | $764K | $491K |
QuarterCharts · SEC EDGAR data · TXMD · Comparing FY2025 (Q4) vs FY2024 (Q4)